This entry is a correction notice to a report on potent, selective, CNS-penetrant macrocyclic LRRK2 inhibitors for Parkinson's disease and contains no new experimental abstract or actionable data.

While LRRK2-targeting, CNS-penetrant macrocyclic inhibitors are highly relevant to PD therapeutic development, a correction notice itself adds little translational value—researchers should consult the original article for the substantive data and implications for drug discovery.